Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.

According to Norwegian registries, 91% of individuals???16 years had received???1 dose of COVID-19 vaccine by mid-July 2022, whereas less than 2% of children?...
SARS-CoV-2 in Norway in the late summer of 2022 by estimating the seroprevalence and identifying antibody profiles based on reactivity to Wuhan or Omicron-like viruses in a nationwide cross-sectional collection of residual sera, and validated our findings using cohort sera.1,914 anonymized convenience sera and 243 NorFlu-cohort sera previously collected from the Oslo-area with reported infection and vaccination status were analyzed for antibodies against spike, the receptor-binding domain (RBD) of the ancestral Wuhan strain and Omicron BA.2 RBD, and nucleocapsid (N). Samples were also tested for antibodies inhibiting RBD-ACE2 interaction. Neutralization assays were performed on subsets of residual sera against B.1, BA.2, XBB.1.5 and BQ.1.1.The national seroprevalence estimate from vaccination and/or infection was 99.1% (95% CrI 97.0-100.0%) based on Wuhan (spike_W and RBD_W) and RBD_BA2 antibodies. Sera from children?
Mesh Terms:
Adolescent, Adult, Aged, Antibodies, Neutralizing, Antibodies, Viral, COVID-19, COVID-19 Vaccines, Child, Child, Preschool, Cross-Sectional Studies, Female, Humans, Infant, Male, Middle Aged, Norway, SARS-CoV-2, Seroepidemiologic Studies, Spike Glycoprotein, Coronavirus, Young Adult
BMC Infect Dis
Date: Aug. 20, 2024
Download Curated Data For This Publication
257454
Switch View:
  • Interactions 1